Bupivacaine - Liquidia Technologies

Drug Profile

Bupivacaine - Liquidia Technologies

Alternative Names: LIQ865; LIQ865A; LIQ865A bupivacaine formulation; LIQ865B; LIQ865B bupivacaine formulation

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Liquidia Technologies
  • Class Analgesics; Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Postoperative pain

Most Recent Events

  • 24 May 2017 Initial efficacy and safety data from a phase I trial in Post-operative pain (In volunteers) released by Liquidia Technologies
  • 24 May 2017 Liquidia Technologies completes a phase I trial in Post-operative pain (In volunteers) in Denmark
  • 01 Feb 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top